CAJ | 학술논문

目的探讨新辅助化疗提高食管癌手术R0切除率的可能性.方法 30例食管癌患者,其中鳞癌18例,腺癌10例,小细胞癌2例.术前新辅助化疗采用以紫杉醇联合铂类为主的方案,化疗后予以手术治疗.结果化疗有效率(CR+PR)56.7%(17/30),R0切除率100%,吻合口瘘发生率3.3% (1/30),无死亡病例.结论新辅助化疗对提高食管癌手术R0切除率具有重要意义,对术后长期生存的影响有待进一步随访观察.
목적 탐토신보조화료제고식관암수술R0절제솔적가능성.방법 30례식관암환자,기중린암18례,선암10례,소세포암2례.술전신보조화료채용이자삼순연합박류위주적방안,화료후여이수술치료.결과 화료유효솔(CR+PR)56.7%(17/30),R0절제솔100%,문합구루발생솔3.3% (1/30),무사망병례.결론 신보조화료대제고식관암수술R0절제솔구유중요의의,대술후장기생존적영향유대진일보수방관찰.
Objective To investigate the possibility of increasing R0 resection rate in esophageal carcinoma after neoadjuvant chemotherapy. Methods 30 patients underwent operation after neoadjuvant chemotherapy mainly by paclitaxel combined with cis-platinum, including 18 squamous carcinoma cases. 10 adenocarcinoma cases and 2 small cell carcinoma cases.Results In these 30 patients,the overall effective rate of neoadjuvant chemotherapy is 56.7%(17/30)(CR+PR),R0 resection rate is 100%,and the incidence rate of anastomotic leakage is 3.3%(1/30),without perioperative death.Conclusion The neoadjuvant chemotherapv is significant in improving the R0 resection rate in esophageal carcinoma,and the impact of long-term survival after surgery needs further follow-up.